We are a cell engineering company focused on commercialising the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development.

Built upon decades of experience in the engineering of cell lines, we have created a unique and high value portfolio of tools and services, which enable almost any gene to be altered or its function modulated, in human and other mammalian cell lines.

Our offerings support and enable critical elements of the drug development and therapeutic value chain, particularly in the area of precision medicine.

Our latest results at a glance

Results for the 12 months ending 31 December 2019 – continuing operations.
  • Group revenue

    £58.3m

    Increase by 7.8%

  • Adjusted EBITDA

    £3.9m

  • Group gross margin

    70.0%

  • Cash

    £18.8m

“Our goal is to leverage our expertise in gene editing and modulation to provide customers with tools and services to transform human health.”

terry pizzie

chief executive officer

Latest news

OUR GROUP AT GLANCE

A world-leader in the design, manufacture application of gene editing and gene modulation tools in life science market.

  • Employees

    416

  • Countries

    12

  • PHDs

    > 85

  • Customers

    > 2000

How we create value

We are focused on commercialising the application of gene editing and gene modulation technologies to accelerate scientific innovation and biopharmaceutical drug development

Our strategy

Our mission is to leverage our expertise in innovative gene editing and gene modulation applications to provide customers with tools and services to transform human health.